<DOC>
	<DOCNO>NCT01411345</DOCNO>
	<brief_summary>1 . The investigator hypothesize increase radiation dose functional MRI-defined lesion prostate bed result improved initial complete response ( reduction prostate-specific antigen ( PSA ) &lt; 0.1 ng/mL ) , related long-term outcome biochemically . 2 . Biomarker expression level differ DCE-MRI enhance non-enhancing tumor region . 3 . 10-15 % men undergo RT free circulate DNA ( fcDNA ) tumor cell ( CTC ) relate adverse treatment outcome . 4 . Prostate cancer-related anxiety reduce MRI target SRT arm , patient aware dominant tumor target high radiation dose .</brief_summary>
	<brief_title>A Phase III Randomized Trial MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy : The MAPS Trial</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>A. Prostate cancer patient PSA prostatectomy least 0.1 ng/mL 4.0 ng/mL within 3 month prior enrollment . B . Patients without palpable abnormality digital rectal exam ( DRE ) eligible . C. Minimum 3 month since prostatectomy allow return urinary continence healing . D. MRI detectable lesion prostate bed . DCEMRI enhance lesion prostate bed least 0.4 cc maximum 6 cc obtain ≤ 3 month prior enrollment . E. No evidence metastatic ( regional distant ) disease pelvic MRI . F. Negative bone scan deem necessary treating physician obtain ≤ 4 month prior enrollment . G. No previous pelvic radiotherapy . H. Serum total testosterone within 40 % normal assay limit , take within 34 month prior enrollment . Patient start androgen deprivation therapy ( ADT ) prior sign consent require serum testosterone range outline ; , serum testosterone level record prior enrollment . I . No concurrent , active malignancy , nonmetastatic skin cancer early stage chronic lymphocytic leukemia ( welldifferentiated small cell lymphocytic lymphoma ) . If prior malignancy remission ≥ 5 year patient eligible . J . Ability understand willingness sign write informed consent document . K. Zubrod performance status &lt; 2 . L. Patients must agree fill quality life/psychosocial questionnaire . M. Age ≥ 35 ≤ 85 year . A . Prior androgen deprivation therapy permit within 6 month previous sign consent form . ( NOTE : Therapy give part plan course radiation allow ) .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Prostate Adenocarcinoma</keyword>
</DOC>